Local News: Westhoff, TX 

 | 

Sign Up

 | 

Sign In

Advertisment

Avonex, Interferon Beta-1a

Avonex, Interferon Beta-1a Wire

Comprehensive News Feed for Avonex, Interferon Beta-1a (generic).

Results 1 - 20 of 34 in Avonex, Interferon Beta-1a (generic)

  1. FDA Holds Up Merck KGaA's Multiple Sclerosis PillRead the original story

    Tuesday Dec 1 | BioSpace

    EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a refuse to file letter from the US Food and Drug Administration on the New Drug Application for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis .

    Comment?

    Related Topix: Food and Drug Administration, Biotech, Medicine, Multiple Sclerosis, Health, Healthcare Industry, Darmstadt, Germany, World News, Hessen, Germany, Germany, Leustatin, Cladribine (generic)

  2. Merck Serono Receives Refuse to File Letter From FDA on Cladribine Tablets New Drug ApplicationRead the original story

    Monday Nov 30 | WEBSPHERE Journal

    "The company will work closely with the FDA to fully understand FDA's concerns and define a path forward for a successful resubmission of this application at the earliest point in time," said , President of Merck Serono.

    Comment?

    Related Topix: Leustatin, Cladribine (generic), Medicine, Food and Drug Administration, Darmstadt, Germany, World News, Hessen, Germany, Germany, Multiple Sclerosis, Health

  3. Merck Serono Receives Refuse to File Letter From FDA on Cladribine Tablets New Drug ApplicationRead the original story

    Monday Nov 30 | SOA World Magazine

    "The company will work closely with the FDA to fully understand FDA's concerns and define a path forward for a successful resubmission of this application at the earliest point in time," said Elmar Schnee , President of Merck Serono.

    Comment?

    Related Topix: Leustatin, Cladribine (generic), Medicine, Food and Drug Administration, Biotech, Healthcare Industry, Darmstadt, Germany, World News, Hessen, Germany, Germany, Multiple Sclerosis, Health

  4. Childbirth May Slow Progression of Multiple SclerosisRead the original story w/Photo

    Tuesday Nov 24 | MedlinePlus

    Having children may slow the progression of multiple sclerosis, new research suggests.

    Comment?

    Related Topix: Medicine, Multiple Sclerosis, Health, Charitable Organizations

  5. Whatever Tysabri Outcome, Biogen Idec Should Survive

    Oct 26, 2009 | BNET

    Biogen Idec 's key multiple sclerosis drug is in the news again, as the European Medicines Agency has started a safety review of Tysabri , citing more confirmed cases of a rare - but potentially fatal - viral infection of the brain, called progressive multifocal leukoencephalopathy , previously linked to the drug.

    Comment?

    Related Topix: Biotech, Biogen Idec, Medicine, Medication, Lymphoma

  6. EMD Serono, Inc. Named as a Top Employer by Science MagazineRead the original story

    Oct 5, 2009 | MELODIKA.net

    EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that Science magazine has named it one of the world's leading biotechnology and pharmaceutical employers.

    Comment?

    Related Topix: Biotech, Healthcare Industry, Darmstadt, Germany, World News, Hessen, Germany, Germany, Science / Technology, Merck

  7. Compelling new data on Novartis' oral MS therapyRead the original story

    Oct 2, 2009 | Drugs.com

    Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression * FREEDOMS study shows FTY720 reduced relapse rates by 54-60% compared to placebo, and disability progression by 30-32%[1] * Results build on Phase III TRANSFORMS one-year study showing FTY720 reduced relapses significantly more ...

    Comment?

    Related Topix: Medicine, Medication, Multiple Sclerosis, Health

  8. Oral Pill Fingolimod Reduces Relapses And Disability ProgressionRead the original story

    Oct 1, 2009 | MediLexicon

    Drug manufacturer Novartis has announced further results from its phase III study of the oral pill fingolimod in people with relapsing remitting multiple sclerosis .

    Comment?

    Related Topix: Medicine, Multiple Sclerosis, Health

  9. Clinical trial results conclude Novartis' MS drug yields 'significant' results

    Oct 1, 2009 | Drug Store News

    BASEL,A Switzerland Patients taking an investigational drug for multiple sclerosis experienced a oesignificanta reductions in relapses and disability progression, according to results of a late-stage clinical trial released Wednesday.

    Comment?

    Related Topix: Medicine, Multiple Sclerosis, Health

  10. Two-year Phase III study shows Novartis oral MS therapy FTY720...

    Sep 29, 2009 | PR-inside.com

    The issuer is solely responsible for the content of this announcement. -------------- * FREEDOMS study shows FTY720 reduced relapse rates by 54-60% compared to placebo, and disability progression by 30-32%[1] * Results build on Phase III TRANSFORMS one-year study showing FTY720 ...

    Comment?

    Related Topix: Biotech, Novartis, Medicine, Medication

  11. Results From Improve Study Show MRI Benefits of Rebif(R) Seen Early...Read the original story

    Sep 11, 2009 | Fox News

    Data Presented at the 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis Held in Dusseldorf, Germany, From September 9-12, 2009.

    Comment?

    Related Topix: Medicine, Multiple Sclerosis, Health, Dusseldorf, Germany, World News, Nordrhein-Westfalen, Germany, Germany, Darmstadt, Germany, Hessen, Germany, Siena, Italy, Italy, Toscana, Italy, Business News

  12. AVONEX results in few injection site reactions, according to a clinical studyRead the original story

    Sep 13, 2009 | News-Medical.Net

    Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on Betaferon- , Copaxone- or Rebif - . The study also showed AVONEX patients were less likely to have missed a dose due to an ...

    Comment?

    Related Topix: Multiple Sclerosis, Health

  13. Phase 2 MS clinical trial data continues to show durable reductions in relapse rateRead the original story

    Sep 13, 2009 | News-Medical.Net

    Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.

    Comment?

    Related Topix: Biotech, Medicine, Genzyme General, Healthcare Industry, Medication, Health

  14. Fewer Injection Site Reactions In Patients Using AVONEX Versus...Read the original story

    Sep 13, 2009 | Medical News Today

    Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on Betaferon , Copaxone or Rebif .

    Comment?

    Related Topix: Multiple Sclerosis

  15. Patients using Avonex have few site reactionsRead the original story

    Sep 11, 2009 | Huliq.com

    Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on BetaferonA , CopaxoneA or Rebif A . The study also showed AVONEX patients were less likely to have missed a dose due to an ...

    Comment?

    Related Topix: Multiple Sclerosis, Health

  16. Genzyme announces results from Phase II of alemtuzumab in multiple sclerosisRead the original story

    Sep 11, 2009 | M2.com

    The CAMMS223 Phase II trial compared alemtuzumab to an approved MS therapy Rebif in early, relapsing-remitting multiple sclerosis patients who had received no prior therapy.

    Comment?

    Related Topix: Medicine, Multiple Sclerosis, Health, Biotech, Genzyme General, Healthcare Industry

  17. Genzyme's Alemtuzumab for Multiple Sclerosis Shows Durable Treatment...

    Sep 11, 2009 | Drugs.com

    Sep 11, 2009 - Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.

    Comment?

    Related Topix: Biotech, Medicine, Genzyme General, Healthcare Industry, Medication

  18. Fewer Injection Site Reactions in Patients Using Avonex Versus...Read the original story

    Sep 11, 2009 | Drugs.com

    Sep 11, 2009 - Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on Betaferon , Copaxone or Rebif .

    Comment?

    Related Topix: Multiple Sclerosis

  19. Results from IMPROVE Study Show MRI Benefits of Rebif Seen Early in...Read the original story

    Sep 11, 2009 | Drugs.com

    Results from IMPROVE Study Show MRI Benefits of Rebif Seen Early in Relapsing-Remitting Multiple Sclerosis Treatment and Sustained Over Time Data presented at the 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis held in Duesseldorf, Germany, from September 9-12, 2009.

    Comment?

    Related Topix: Medicine, Multiple Sclerosis, Health, Siena, Italy, Italy, World News, Toscana, Italy

  20. 16:41]( ... )- ' ' s Y - Y - BW- Fewer Injection Site...Read the original story

    Sep 11, 2009 | ANA - Athens News Agency

    I'I I'IsIYI I I I I- I I I IYI - BW- Fewer Injection Site Reactions in Patients Using AVONEXA Versus Sub... Fewer Injection Site Reactions in Patients Using AVONEXA Versus Sub-cutaneous Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis CAMBRIDGE, Mass.-- -- Data from an observational phase IV study of 499 patients ...

    Comment?

    Related Topix: Multiple Sclerosis